Related Experiment Video
Updated: May 14, 2025

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Effectiveness of AI-driven interventions in glycemic control: A systematic review and meta-analysis of randomized
Khadija Elmotia1, Oumaima Abouyaala1, Soukaina Bougrine1
1Laboratory of Biology and Health, Department of Biology, Faculty of Science, Ibn Tofail University, BP 133, Kenitra, Morocco.
Abstract:
This systematic review aims to assess the effectiveness of AI-Driven Decision Support Systems in improving glycemic control, measured by Time in Range (TIR) and HbA1c levels, in patients with diabetes. Included studies were randomized controlled trials (RCTs) that evaluated AI interventions in diabetes management. Exclusion criteria included non-English studies, non-peer-reviewed articles. Studies were identified by searching electronic databases including PubMed, EMBASE, and Cochrane Library up to December 2024. Risk of bias was assessed using the Cochrane Risk of Bias tool for RCTs. Results were synthesized using a random-effects meta-analysis model. The review included 17 RCTs with a total of 3381 participants in the intervention group and 3176 in the control group. AI interventions were found to significantly improve TIR and reduce HbA1c levels. The meta-analysis for TIR yielded a mean difference of 0.54 (95 % CI: 0.05-1.03), and for HbA1c a standardized mean difference of -0.91 (95 % CI: -1.23 to -0.58). Evidence was limited by high heterogeneity (I² > 90 % for both outcomes) and indications of publication bias, which may overestimate the effectiveness reported. Despite limitations, the results support the potential of AI interventions in enhancing diabetes management, though variability in effectiveness suggests the need for personalized approaches.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Dipeptidyl Peptidase 4 Inhibitors
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Diabetes Mellitus: Type 2 and Gestational

